Komori
Kohjin Bio (177A) · InitiativeRestated

Strengthening consultative sales of domestically produced culture media for bacterial testing

First written in FY2024. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025-H1 – FY20252024: 220242025: 120252026: 12026
Same theme, other companies

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「In Japan's bacterial testing market, culture media for bacterial testing used in industrial sectors such as pharmaceuticals, food and cosmetics are seeing demand shift from imported products, whose supply is unstable and prices rise periodically, to domestically produced products. We will therefore strengthen proposal-based sales by leveraging the advantages of domestic production.」

    We continue to pursue a policy of strengthening proposal-based sales of domestically produced products against a backdrop of supply and pricing issues affecting imported products.
  2. FY2025AdvancedAnnual report

    「In the industrial bacterial testing market, including pharmaceutical companies, the market share of our Group's products, which offer lower prices and stable supply than competing imported products, is expanding.」

    The company reported market share gains for domestically produced bacterial testing media, supported by their lower prices and stable supply compared with imported products.
  3. FY2025-H1AdvancedAnnual report

    「In the industrial sector, including pharmaceutical companies, prices of competing imported bacterial testing products from overseas have increased against a backdrop including the weaker yen. Our decision to hold prices steady to expand market share paid off, resulting in an increase in sales volume of our products.」

    The company held prices steady while imported products were undergoing price increases, and reported an increase in sales volume of its products in the industrial sector.
  4. FY2024First statedAnnual report

    「As there is demand to switch from imported products, whose supply is unstable and prices rise periodically, to domestically produced products, we will strengthen proposal-based sales by leveraging the advantages of domestic production.」

    We will use supply and pricing issues affecting imported products as an opportunity to strengthen sales of domestically manufactured products.
Moved together

"Expansion of Production Facilities and Strengthening of R&D Capabilities" moved the same way as this thread, in the same document, in 2 of its 4 moves.

2222★1234
  1. ★This thread
  2. 1Expansion of Production Facilities and Strengthening of R&D Capabilities2×
  3. 2Expansion of the Regenerative Medicine Market2×
  4. 3Entry into Contract Manufacturing of Cells for Clinical Trials of Regenerative Medical Products2×
  5. 4Listing on the Tokyo Stock Exchange Growth Market and growth investment2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kohjin Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening consultative sales of domestically produced culture media for bacterial testing | Kohjin Bio Co.,Ltd. (177A) | Komori